Active Ingredient	Daclatasvir Dihydrochloride
Manufacturer	Natco
Origin	India
Reference	N/A

What is Natdac (Daclatasvir Dihydrochloride) used for?

Natdac (Daclatasvir Dihydrochloride) is a treatment for chronic hepatitis C virus (HCV). It is a is a direct-acting antiviral agent that inhibits both viral RNA replication and virion assembly. It is prescribed to treat paients with genotype 1 or genotype 3 infection. It is always prescribed with sofosbuvir, or with sofosbuvir and ribavirin.

How should I use Natdac (Daclatasvir Dihydrochloride)?

Except in certain circumstances, the general dosage is one 60mg tablet daily taken for a period of 12 weeks. Natdac is an oral tablet that should be swallowed whole with a glass of water. It can be taken with or without food.

Natdac will be always prescribed with Sofosbuvir, and in some cases it will be prescribed with Ribavarin also. Ribavirin will be prescribed:

• in post-transplant patients
• in patients with decompensated cirrhosis
• in patients with Genotype 3 infection and compensated cirrhosis

What are the side effects of Natdac (Daclatasvir Dihydrochloride)?

Natdac (Daclatasvir Dihydrochloride) can cause some unwanted side effects for some patients. Most side effects can be classified as mild to moderate and are often only temporary. The most commonly reported side effects are headache, fatigue, nausea and diarrhea. Ribavirin can casue additional side effects such as anemia, rash, insomnia, dizziness and somnolence.

Please Note

Daclatasvir Dihydrochloride, Sofosbuvir and Amiodarone (especially if beta-blockers are also being taken) together can sometimes lead to symptomatic bradycardia.

Daclatasvir and certain other medicinaes can have a negative impact on each other. Tell your doctor if you are taking:

• Protease inhibitors (atazanavir with ritonavir, indinavir, nelfinavir, saquinavir)
• Other antiretrovirals (eg. atazanavir/cobicistat, elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate)
• Non-nucleoside reverse transcriptase inhibitors (efavirenzb, etravirine, nevirapine)
• Strong CYP3A inhibitors (eg. clarithromycin, itraconazole, ketoconazole, nefazodone, posaconazole, telithromycin, voriconazole)
• Strong CYP3A inducers (eg. phenytoin, carbamazepine, rifampin, St. John's wort)
• Moderate CYP3A inducers (eg. bosentan, dexamethasone, modafinil, nafcillin, rifapentine)
• Anticoagulants (dabigatran etexilate mesylate)
• Cardiovascular agents (Amiodarone, Digoxin)
• HMG-CoA reductase inhibitors (Atorvastatin, Fluvastatin, Pitavastatin, Pravastatin, Rosuvastatin, Simvastatin)
• Narcotic Analgesics (buprenorphine, buprenorphine/naloxone)

Daclatasvir can increase the risk of birth defects and miscarriage. Men whose partners are pregnant, pregnant women, women who are trying to become pregnant, and men whose partners are trying to become pregnant shoulde exercise care and check with their doctor before using Daclatasvir.

Daclatasvir may not be safe to use in patients under 18 years old.